Skip Page Header

Home > Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP).

European Monitoring Centre for Drugs and Drug Addiction. (2016) Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP). Luxembourg: Publications Office of the European Union. Risk Assessments 18.

[img]
Preview
PDF (Risk assessment a-pvp)
638kB

This publication presents the data and findings of the risk assessment on α-PVP (1-phenyl- 2-(1-pyrrolidinyl)-1-pentanone), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2015. α-PVP is the eleventh new psychoactive substance to be risk assessed under the terms of Council Decision 2005/387/JHA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 June 2016, the Council decided that α-PVP should be subject to control measures across the Member States.

 

Table of contents

  • Foreword
  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA–Europol Joint Report on α-PVP: a summary
  • Risk Assessment Report of a new psychoactive substance: α-PVP
  • Annex 1: Technical report on α-PVP
  • Council Decision on subjecting α-PVP to control measures
  • Participants of the risk assessment meeting
Item Type
Report
Publication Type
International, Report
Drug Type
New psychoactive substance
Intervention Type
Harm reduction
Source
Date
July 2016
Identification #
Risk Assessments 18
Pages
48 p.
Publisher
Publications Office of the European Union
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote

Repository Staff Only: item control page